跳至主要内容
临床试验/NCT00810472
NCT00810472已完成不适用

Clinical Trial to Investigate Superiority of HLA Matching in Comparison to Random Graft Assignment With Respect to the Endpoint 'Time to First Endothelial Graft Rejection' in Penetrating Keratoplasty.

University Hospital Freiburg2 个研究点 分布在 1 个国家目标入组 650 人开始时间: 2009年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
650
试验地点
2
主要终点
Time to first endothelial graft rejection.

研究概览

简要总结

Penetrating keratoplasty is one of the most commonly performed transplantation surgeries. Graft rejection is a major complication. HLA compatibility has already been demonstrated an effective prophylaxis in several retrospective investigations. The purpose of the investigators randomized clinical trial is to demonstrate superiority of HLA matching in comparison to random graft assignment with respect to the endpoint 'time to first endothelial graft rejection' in penetrating keratoplasty. The investigators will perform DNA-based allele resolution typing.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Predicted waiting time for a 4/6 match lower than 6 months.

排除标准

  • Legal incapacity

结局指标

主要结局

Time to first endothelial graft rejection.

时间窗: Mostly within the first six months.

次要结局

未报告次要终点

研究者

发起方
University Hospital Freiburg
申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniel Böhringer

Apl.Prof.Dr.med.

University Hospital Freiburg

研究点 (2)

Loading locations...

相似试验